Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Lee430on Apr 15, 2021 11:59am
91 Views
Post# 33000845

RE:RE:NBF report is out

RE:RE:NBF report is outWino,
If I recall correctly these are the two I did not vote for last year and when looking at the vote tabulation I was not alone in that effort....Hopefully some of the highly experienced members of this board will help pull us together as one LARGE voice for some common sense change.  ”Common sense is not so common”


Wino115 wrote: If NBF didn't at least review oncology and how the trial just started and what the significant data story told, then it's criminal and clearly a blow-off of the mangement and name. If I recall, his target is well below the current price so if he didn't change it, he is on a sell and believes you will lose money over the next 12-18 months.

 This explains two things -- why we keep seeing NBF participating heaviliy in trading as their clients jettison it since their analyst thinks it's wildly overvalued and likely telling clients to sell if they ask; and, two, Leno is an incompetent nincomepoop, and not just because he doesnt' agree with me, but because he doesn't even know the key issues that will drive the share price.  If Paul had any sense, he'd completely shut off any relationship with these Knights of Nee idiots.

We also now have out list of which Board members to boot off:  The two with NBF ties -- Paul Pommier and Gary Littlejohn. If either is up for election, time to send our message! They will not be getting my votes. 


SPCEO1 wrote: I am not sure you could really call it a report, however. Not much effort was expended in producing it - I am guessing he may have dedicated 30 minutes to this. It is more evidence of bad blood between the company and Bay Street. The analyst, however, did not reduce his target price, however. Which I was surprised about given the revenue shortfall.

Like all of us, the NBF analyst is perturbed by the jumpy quarterly sales trends. I think that can partly be blamed on attempts to manage quarterly sales, as noted earlier, by stuffing the distribution channel in one quarter and hoping sales pick up enough in the following quarter to cover your tracks. But that pick-up never happens and sales look lumpier than they probably actually are on the ground.




<< Previous
Bullboard Posts
Next >>